Skip to content

Study · Randomized controlled trial · 2020

7 results

Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLD.

Fourman LT, Billingsley JM, Agyapong G, Ho Sui SJ, Feldpausch MN, Purdy J, Zheng I, Pan CS, Corey KE, Torriani M, Kleiner DE, Hadigan CM, Stanley TL, Chung RT, Grinspoon SK

JCI insight20 Aug 2020Cited by 21 (Europe PMC)

PMID32701508 (opens in a new tab)PMCIDPMC7455119 (opens in a new tab)DOI10.1172/jci.insight.140134 (opens in a new tab)PepBankPUB-32701508
Download PDFPubMedAsk about this study
Jump to 7 results

Summary

Nonalcoholic fatty liver disease (NAFLD) is a common comorbidity among people living with HIV that has a more aggressive course than NAFLD among the general population. In a recent randomized placebo-controlled trial, we demonstrated that the growth hormone-releasing hormone analog tesamorelin reduced liver fat and prevented fibrosis progression in HIV-associated NAFLD over 1 year. As such, tesamorelin is the first strategy that has shown to be effective against NAFLD among the population with HIV. The current study leveraged paired liver biopsy specimens from this trial to identify hepatic gene pathways that are differentially modulated by tesamorelin versus placebo. Using gene set enrichment analysis, we found that tesamorelin increased hepatic expression of hallmark gene sets involved in oxidative phosphorylation and decreased hepatic expression of gene sets contributing to inflammation, tissue repair, and cell division. Tesamorelin also reciprocally up- and downregulated curated gene sets associated with favorable and poor hepatocellular carcinoma prognosis, respectively. Notably, among tesamorelin-treated participants, these changes in hepatic expression correlated with improved fibrosis-related gene score. Our findings inform our knowledge of the biology of pulsatile growth hormone action and provide a mechanistic basis for the observed clinical effects of tesamorelin on the liver.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

  1. 01HumanRandomized controlled trialMechanism

    In people with HIV-associated NAFLD, tesamorelin increased hepatic expression of gene sets for oxidative phosphorylation versus placebo.

    In plain wordsIn people with HIV and fatty liver, tesamorelin raised liver activity of genes for energy production more than placebo did.

    Peptide
    Tesamorelin
    Outcome
    IncreaseHepatic oxidative phosphorylation gene sets
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Mitochondrial function · Liver
    Studied dose
    Dose not stated · 1 yearAs given in this study (human).

    Source sentences

    Summary
    Using gene set enrichment analysis, we found that tesamorelin increased hepatic expression of hallmark gene sets involved in oxidative phosphorylation and decreased hepatic expression of gene sets contributing to inflammation, tissue repair, and cell division.
    1 context sentence
    Summary · context
    The current study leveraged paired liver biopsy specimens from this trial to identify hepatic gene pathways that are differentially modulated by tesamorelin versus placebo.
  2. 02HumanRandomized controlled trialMechanism

    In people with HIV-associated NAFLD, tesamorelin decreased hepatic expression of gene sets for inflammation versus placebo.

    In plain wordsIn people with HIV and fatty liver, tesamorelin lowered liver activity of inflammation genes more than placebo did.

    Peptide
    Tesamorelin
    Outcome
    DecreaseHepatic inflammation gene sets
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    Dose not stated · 1 yearAs given in this study (human).

    Source sentences

    Summary
    Using gene set enrichment analysis, we found that tesamorelin increased hepatic expression of hallmark gene sets involved in oxidative phosphorylation and decreased hepatic expression of gene sets contributing to inflammation, tissue repair, and cell division.
    1 context sentence
    Summary · context
    The current study leveraged paired liver biopsy specimens from this trial to identify hepatic gene pathways that are differentially modulated by tesamorelin versus placebo.
  3. 03HumanRandomized controlled trialMechanism

    In people with HIV-associated NAFLD, tesamorelin decreased hepatic expression of gene sets for tissue repair versus placebo.

    In plain wordsIn people with HIV and fatty liver, tesamorelin lowered liver activity of tissue repair genes more than placebo did.

    Peptide
    Tesamorelin
    Outcome
    DecreaseHepatic tissue repair gene sets
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    Dose not stated · 1 yearAs given in this study (human).

    Source sentences

    Summary
    Using gene set enrichment analysis, we found that tesamorelin increased hepatic expression of hallmark gene sets involved in oxidative phosphorylation and decreased hepatic expression of gene sets contributing to inflammation, tissue repair, and cell division.
    1 context sentence
    Summary · context
    The current study leveraged paired liver biopsy specimens from this trial to identify hepatic gene pathways that are differentially modulated by tesamorelin versus placebo.
  4. 04HumanRandomized controlled trialMechanism

    In people with HIV-associated NAFLD, tesamorelin decreased hepatic expression of gene sets for cell division versus placebo.

    In plain wordsIn people with HIV and fatty liver, tesamorelin lowered liver activity of cell division genes more than placebo did.

    Peptide
    Tesamorelin
    Outcome
    DecreaseHepatic cell division gene sets
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    Dose not stated · 1 yearAs given in this study (human).

    Source sentences

    Summary
    Using gene set enrichment analysis, we found that tesamorelin increased hepatic expression of hallmark gene sets involved in oxidative phosphorylation and decreased hepatic expression of gene sets contributing to inflammation, tissue repair, and cell division.
    1 context sentence
    Summary · context
    The current study leveraged paired liver biopsy specimens from this trial to identify hepatic gene pathways that are differentially modulated by tesamorelin versus placebo.
  5. 05HumanRandomized controlled trialMechanism

    In people with HIV-associated NAFLD, tesamorelin up-regulated curated gene sets associated with favorable hepatocellular carcinoma prognosis.

    In plain wordsIn people with HIV and fatty liver, tesamorelin raised liver activity of genes linked to a better liver cancer outlook.

    Peptide
    Tesamorelin
    Outcome
    IncreaseHepatocellular carcinoma favorable-prognosis gene sets
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Liver fat and liver function · Cancer
    Studied dose
    Dose not stated · 1 yearAs given in this study (human).

    Source sentences

    Summary
    Tesamorelin also reciprocally up- and downregulated curated gene sets associated with favorable and poor hepatocellular carcinoma prognosis, respectively.
    1 context sentence
    Summary · context
    The current study leveraged paired liver biopsy specimens from this trial to identify hepatic gene pathways that are differentially modulated by tesamorelin versus placebo.
  6. 06HumanRandomized controlled trialMechanism

    In people with HIV-associated NAFLD, tesamorelin down-regulated curated gene sets associated with poor hepatocellular carcinoma prognosis.

    In plain wordsIn people with HIV and fatty liver, tesamorelin lowered liver activity of genes linked to a worse liver cancer outlook.

    Peptide
    Tesamorelin
    Outcome
    DecreaseHepatocellular carcinoma poor-prognosis gene sets
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Liver fat and liver function · Cancer
    Studied dose
    Dose not stated · 1 yearAs given in this study (human).

    Source sentences

    Summary
    Tesamorelin also reciprocally up- and downregulated curated gene sets associated with favorable and poor hepatocellular carcinoma prognosis, respectively.
    1 context sentence
    Summary · context
    The current study leveraged paired liver biopsy specimens from this trial to identify hepatic gene pathways that are differentially modulated by tesamorelin versus placebo.
  7. 07HumanRandomized controlled trialMechanism

    Among tesamorelin-treated participants with HIV-associated NAFLD, changes in hepatic gene expression correlated with improved fibrosis-related gene score.

    In plain wordsIn people with HIV and fatty liver given tesamorelin, changes in liver gene activity were linked to an improved fibrosis-related gene score.

    Peptide
    Tesamorelin
    Outcome
    Not applicableCorrelation of hepatic expression changes with fibrosis-related gene score
    Study

    n: not reported in source

    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    Dose not stated · 1 yearAs given in this study (human).

    Source sentences

    Summary
    Notably, among tesamorelin-treated participants, these changes in hepatic expression correlated with improved fibrosis-related gene score.
    1 context sentence
    Summary · context
    The current study leveraged paired liver biopsy specimens from this trial to identify hepatic gene pathways that are differentially modulated by tesamorelin versus placebo.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 19:08 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:13 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.